Cue Biopharma Competitors and Similar CompaniesClear all

Cue Biopharma's competitors and similar companies include Sorrento Therapeutics, Catalyst Pharmaceuticals, Momenta Pharmaceuticals and Alnylam.
Cue Biopharma
Cue Biopharma
Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease.
Sorrento Therapeutics
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
Momenta Pharmaceuticals
Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Alnylam
Alnylam
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
Founding Date
Founding Date
2015
Founding Date
2006
Founding Date
2002
Founding Date
2001
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Locations
San Diego, US HQ
San Diego, US
Locations
Coral Gables, US HQ
Locations
Cambridge, US HQ
Dublin, IE
Cambridge, US
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Employees
Employees
4664% increase
Employees
31019% decrease
Employees
7649% increase
Employees
761% decrease
Employees
1,32324% increase
Valuation ($)
Valuation ($)
107.3 m
Valuation ($)
1.5 m
Valuation ($)
2.6 b
Valuation ($)
N/A
Valuation ($)
36.5 b

Financial

Revenue (est.)
Revenue (est.)
$9.3m (FY, 2024)
Revenue (est.)
$62.8m (FY, 2022)
Revenue (est.)
$491.7m (FY, 2024)
Revenue (est.)
$23.9m (FY, 2019)
Revenue (est.)
$2.2b (FY, 2024)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$68.8m (FY, 2024)
Cost of goods
N/A
Cost of goods
$306.5m (FY, 2024)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$422.9m (FY, 2024)
Gross profit
N/A
Gross profit
$1.9b (FY, 2024)
Net income
Net income
($40.7m) (FY, 2024)
Net income
($577.8m) (FY, 2022)
Net income
$163.9m (FY, 2024)
Net income
($290.1m) (FY, 2019)
Net income
($278.2m) (FY, 2024)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 42.6m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 1.5b
For sources of this data, please see the company profile

View Company Profiles

Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.

View company
Catalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.

View company
Momenta Pharmaceuticals
HQ
Cambridge, US

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.

View company
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.

View company